These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 27565273)

  • 1. On the Estimation of the Cost-Effectiveness Threshold: Why, What, How?
    Vallejo-Torres L; García-Lorenzo B; Castilla I; Valcárcel-Nazco C; García-Pérez L; Linertová R; Polentinos-Castro E; Serrano-Aguilar P
    Value Health; 2016; 19(5):558-66. PubMed ID: 27565273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.
    Claxton K; Martin S; Soares M; Rice N; Spackman E; Hinde S; Devlin N; Smith PC; Sculpher M
    Health Technol Assess; 2015 Feb; 19(14):1-503, v-vi. PubMed ID: 25692211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research.
    Woods B; Revill P; Sculpher M; Claxton K
    Value Health; 2016 Dec; 19(8):929-935. PubMed ID: 27987642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Societal Preferences for Interventions with the Same Efficiency: Assessment and Application to Decision Making.
    Shiroiwa T; Saito S; Shimozuma K; Kodama S; Noto S; Fukuda T
    Appl Health Econ Health Policy; 2016 Jun; 14(3):375-85. PubMed ID: 26940671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of Decision Makers' Constraints on the Outcome of Value of Information Analysis.
    Koffijberg H; Knies S; Janssen MP
    Value Health; 2018 Feb; 21(2):203-209. PubMed ID: 29477402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.
    Barbieri M; Drummond M; Willke R; Chancellor J; Jolain B; Towse A
    Value Health; 2005; 8(1):10-23. PubMed ID: 15841890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].
    Garrison LP; Neumann PJ; Willke RJ; Basu A; Danzon PM; Doshi JA; Drummond MF; Lakdawalla DN; Pauly MV; Phelps CE; Ramsey SD; Towse A; Weinstein MC
    Value Health; 2018 Feb; 21(2):161-165. PubMed ID: 29477394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: An Economic Analysis.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2016; 16(6):1-51. PubMed ID: 27110317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.
    Crathorne L; Huxley N; Haasova M; Snowsill T; Jones-Hughes T; Hoyle M; Briscoe S; Coelho H; Long L; Medina-Lara A; Mujica-Mota R; Napier M; Hyde C
    Health Technol Assess; 2016 Feb; 20(13):1-588, v-vi. PubMed ID: 26907163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of Change in the Cost-effectiveness Threshold.
    Paulden M; O'Mahony J; McCabe C
    Med Decis Making; 2017 Feb; 37(2):264-276. PubMed ID: 27553208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
    Saborido CM; Hockenhull J; Bagust A; Boland A; Dickson R; Todd D
    Health Technol Assess; 2010 Jun; 14(31):iii-iv, 1-75. PubMed ID: 20569652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updating Cost Effectiveness Analyses in Orthopedic Surgery: Resilience of the $50,000 per QALY Threshold.
    Nwachukwu BU; Bozic KJ
    J Arthroplasty; 2015 Jul; 30(7):1118-20. PubMed ID: 25737385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond QALYs: Multi-criteria based estimation of maximum willingness to pay for health technologies.
    Nord E
    Eur J Health Econ; 2018 Mar; 19(2):267-275. PubMed ID: 28258399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sepsis: the LightCycler SeptiFast Test MGRADE®, SepsiTest™ and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi - a systematic review and economic evaluation.
    Stevenson M; Pandor A; Martyn-St James M; Rafia R; Uttley L; Stevens J; Sanderson J; Wong R; Perkins GD; McMullan R; Dark P
    Health Technol Assess; 2016 Jun; 20(46):1-246. PubMed ID: 27355222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous positive airway pressure devices for the treatment of obstructive sleep apnoea-hypopnoea syndrome: a systematic review and economic analysis.
    McDaid C; Griffin S; Weatherly H; Durée K; van der Burgt M; van Hout S; Akers J; Davies RJ; Sculpher M; Westwood M
    Health Technol Assess; 2009 Jan; 13(4):iii-iv, xi-xiv, 1-119, 143-274. PubMed ID: 19103134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local health care expenditure plans and their opportunity costs.
    Karlsberg Schaffer S; Sussex J; Devlin N; Walker A
    Health Policy; 2015 Sep; 119(9):1237-44. PubMed ID: 26251323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Some inconsistencies in NICE's consideration of social values.
    Paulden M; O'Mahony JF; Culyer AJ; McCabe C
    Pharmacoeconomics; 2014 Nov; 32(11):1043-53. PubMed ID: 25145802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severity-Adjusted Probability of Being Cost Effective.
    Versteegh MM; Ramos IC; Buyukkaramikli NC; Ansaripour A; Reckers-Droog VT; Brouwer WBF
    Pharmacoeconomics; 2019 Sep; 37(9):1155-1163. PubMed ID: 31134467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.